Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A kind of anti-h1n1 influenza pharmaceutical composition and application thereof

A composition and drug technology, applied in the direction of pharmaceutical formula, antiviral agents, plant raw materials, etc., can solve the problems of Tamiflu’s severe side effects, inapplicability to young people, and insufficient drug production capacity, so as to improve the survival rate and prolong the average survival time , Prevention and treatment of H1N1 infection

Active Publication Date: 2020-12-04
INST OF TROPICAL BIOSCI & BIOTECH CHINESE ACADEMY OF TROPICAL AGRI SCI
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In recent years, influenza A (H1N1) or its variant viruses have caused influenza epidemics in many places, but the neuraminidase inhibitor oseltamivir (Tamiflu), which can fight against influenza A (H1N1), is patented by Roche. Insufficient drug production capacity, and Tamiflu’s side effects are relatively large, and it is not suitable for teenagers. Many cases of Tamiflu-resistant influenza A cases have been discovered successively, posing a huge threat to human health

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A kind of anti-h1n1 influenza pharmaceutical composition and application thereof
  • A kind of anti-h1n1 influenza pharmaceutical composition and application thereof
  • A kind of anti-h1n1 influenza pharmaceutical composition and application thereof

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0041] In addition, in order to facilitate the preparation of the pharmaceutical composition of the present invention into various medicaments more conveniently, the preparation method of the present invention also includes:

[0042] At 50-60°C, the filtrate obtained after ethanol extraction was concentrated into a thick paste.

[0043] Wherein, the relative density of the thick paste is preferably 1.10-1.15.

[0044] When the pharmaceutical composition of the present invention was compared with the inosine monophosphate dehydrogenase inhibitor ribavirin for inhibiting influenza A H1N1 virus in canine kidney MDCK cells in vitro, it was found that the inhibitory activity of the pharmaceutical composition was better than that of ribavirin. Bavirin; in the mouse nasal drop infection pneumonia test, the pharmaceutical composition of the present invention can significantly reduce the viral load and lung index of the lung tissue, and the inhibition rate of influenza A H1N1 influenza...

Embodiment 1

[0049] Example 1: Preparation of capsules of the pharmaceutical composition of the present invention

[0050] Take by weighing each crude drug (unit: g) by following weight: marine organism extract 30, Chinese medicine composition extract 80;

[0051] Get marine organisms (the proportion is 1 part of starfish and 6 parts of seaweed), the traditional Chinese medicine composition (the proportion is 7 parts of burdock, 4 parts of mulberry leaves, 5 parts of honeysuckle, 4 parts of forsythia, 6 parts of scutellaria baicalensis), add 7 parts respectively. 70% ethanol reflux extraction twice the total weight of the extract, 60min each time, filtered, the filtrate was concentrated under reduced pressure at 55 ° C to a thick paste with a relative density of 1.10-1.15, spray-dried to obtain the raw material drug (Marine Biologicals). extracts and traditional Chinese medicine composition extracts). The crude drug is weighed according to the above weight, sodium starch glycolate is adde...

Embodiment 2

[0052] Example 2: Preparation of tablets of the pharmaceutical composition of the present invention

[0053] Take by weighing each raw material medicine (unit: g) by following weight: marine organism extract 20, Chinese medicine composition extract 70;

[0054] Get marine organisms (the proportion is 1 part of starfish and 8 parts of seaweed), the traditional Chinese medicine composition (the proportion is 6 parts of burdock seed, 3 parts of mulberry leaf, 7 parts of honeysuckle, 2 parts of forsythia, 5 parts of skullcap), add 6 parts respectively. 90% ethanol twice the total weight of the extract was refluxed for 3 times, 60min each time, filtered, the filtrate was concentrated under reduced pressure at 50°C to a thick paste with a relative density of 1.10-1.15, and spray-dried to obtain the bulk drug. Weigh the crude drug according to the above weight, add sodium starch glycolate, mix well, and send it into a tablet press to form a tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of medicines and discloses an anti-A(H1N1) flu pharmaceutical composition and application thereof. The pharmaceutical composition comprises marine organisms and a traditional Chinese medicine composition. The efficient and safe pharmaceutical composition prepared from seven natural medicines has an anti-A(H1N1) flu effect, is good in curative effect, has no toxic or side effect and no drug dependence for human bodies, and is superior to the conventional drug preparation product; therefore, the pharmaceutical composition can be widely applied in preparation of an anti-A(H1N1) flu drug.

Description

technical field [0001] The invention relates to the field of medicine, in particular to an anti-H1N1 influenza medicine composition and application thereof. Background technique [0002] Influenza A (H1N1) is a zoonotic acute respiratory infectious disease. Its pathogen is a new type of influenza A (H1N1) virus, belonging to the Orthomyxidae family, and is a single-stranded negative-stranded RNA virus. Unlike previous or current seasonal flu viruses, the virus strain contains genetic fragments from three influenza viruses, swine flu, avian flu and human flu. The population is generally susceptible to influenza A (H1N1) virus and can be transmitted from person to person. The early symptoms of human infection with influenza A are similar to those of ordinary influenza, including fever, cough, sore throat, body pain, headache, chills and fatigue. If the individual's physical fitness is poor and their own immunity is low, the patient's condition may progress rapidly after being...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/634A61P31/16A61K35/616
CPCA61K35/616A61K36/02A61K36/28A61K36/355A61K36/539A61K36/605A61K36/634A61K2236/333A61K2236/39A61K2236/51A61K2300/00
Inventor 赵友兴周丽曼马青云孔凡栋谢晴宜戴好富
Owner INST OF TROPICAL BIOSCI & BIOTECH CHINESE ACADEMY OF TROPICAL AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com